Alnylam Pharmaceuticals
By therapeutic area
Not enough TA-specific data (need ≥3 deals per TA).
By stage at signing
Not enough phase-specific data (need ≥3 deals per phase).
Strategy profile
Based on 8 disclosed transactions, Alnylam Pharmaceuticals concentrates its licensing activity in Other, RareDisease, and Cardiovascular. Alnylam Pharmaceuticals pays a 1.50x premium over market median. Their most common deal structure is Collaboration, with an average disclosed value of $1.9B. Most recent activity: 2026.
Pipeline coverage & gaps
Alnylam Pharmaceuticals has disclosed activity in 0 of 12 tracked therapeutic areas. Gaps may represent whitespace opportunities for licensors.
Deal type breakdown
How this buyer structures its transactions
| Deal type | Count | Avg upfront | Avg total value |
|---|---|---|---|
| CollaborationPrimary | 8 | $216M | $1.9B |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2026 | AI-driven RNA therapeutics platform | Inceptive | — | discovery | — | $2.0B |
| 2026 | AI-driven RNAi discovery collaboration | Inceptive | multiple therapeutic areas | discovery | — | $2.0B |
| 2026 | AI-designed RNA therapeutics platform | Inceptive Therapeutics | genetic diseases | discovery | — | $2.0B |
| 2026 | AI-assisted siRNA design platform collaboration | Inceptive Nucleics | multiple indications | discovery | $30M | $2.0B |
| 2026 | AI-designed siRNA candidates | Inceptive Nucleics | — | discovery | $30M | $1.1B |
| 2026 | — | Tenaya Therapeutics Inc. | heart disease | discovery | $10M | $1.1B |
| 2024 | rareNeuro | Regeneron | rareNeuro | preclinical | $1.0B | $3.4B |
| 2024 | Cardiovascular RNAi programs | Tenaya Therapeutics | Heart Failure, Cardiomyopathy | preclinical | $10M | $1.1B |
How this is computed
For each Alnylam Pharmaceuticals deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 3 disclosed deal premiums vs. peer medians. Raw premium 1.611, clamped to [0.7, 1.5].